EHA2023レポート② Late-breaking Session

慢性ITPに対するSYK阻害薬cevidoplenibの第Ⅱ相試験
有効性・安全性ともに良好 CEVIDOPLENIB, A SELECTIVE INHIBITOR OF SPLEEN TYROSINE KINASE (SYK), IN PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): EFFICACY AND SAFETY IN A MULTICENTER, PLACEBO CONTROLLED PHASE 2 STUDY (#LB2712)

Jun-Ho Jang（Division Of Hematology Oncology, Samsung Medical Center, Seoul, Korea, Rep. Of South）